ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 614

Causes Of Mortality In Lupus Patients Followed Prospectively At a Large Single-Centre Lupus Clinic

Barry J. Sheane, Dominique Ibanez, Dafna D. Gladman and Murray B. Urowitz, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Death and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Survival rates of patients with systemic lupus erythematosus (SLE) have improved significantly over the last four decades. Mortality rates remain high, however, and are almost 4 times that of the general population. A bi-modal pattern of mortality in SLE has been described whereby death within the first year after diagnosis was associated with active lupus and infection, while death in later years was associated with atherosclerosis and corticosteroid use.

The aim of this study was to re-examine the causes of mortality in lupus patients followed prospectively at a large lupus clinic between 1970 and 2013.

Methods:

Causes of death were recorded and acquired from autopsy reports (n=48), discharge summaries (n=64), hospital notes (n=23), and death certificates (n=20). Causes were divided into 5 categories: active lupus, atherosclerosis-related, infection, malignancy and ‘other’, and designated as either a ‘primary’ or ‘secondary’ cause.  Atherosclerosis-related (AS) deaths were those attributable to acute myocardial infarction, congestive cardiac failure (as a direct result of coronary artery disease), or stroke, all in the absence of active SLE. ‘Other’ causes referred to those that were not attributable to active SLE, atherosclerosis, infection or malignancy.

Results:

Out of 264 patients known to have died, causes of death were established in 206 cases. Mean disease duration at time of death was 14.6 ± 11.8 years, with 47 (23%) dying within 5 years and 62 (30%) dying 20 or more years after diagnosis. Mean age at death was 52.6 ± 17.5 years, with 56 (27%) dying before the age of 40. Infection was responsible for the majority of deaths (n=71 (34.5%)), followed by active SLE (n=38 (18.4%)), AS (n=38 (18.4%)), malignancy (n=24 (11.7%)) and ‘other’ (n=60 (29.1%)). Renal failure in inactive SLE (n=6) and bowel perforation (n=5) were among ‘other’ causes.

There was a significant decline in the number of deaths attributable to infection and active SLE with increasing disease duration: 49% (n=23) and 34%(n=16) of deaths in those with SLE for less than 5 years were due to infection and active lupus, respectively, compared with 26% (n=16) and 15% (n=9) of deaths in those with SLE for 20 or more years (p=0.01). Atherosclerosis was increasingly responsible for death with increasing disease duration: 13% (n=5) with less than 5 years disease duration, compared with 23% (n=14) after 20 years of SLE (p=0.11). Malignancy also increased in prevalence as a cause of death with greater disease duration (p=0.13).

Conclusion:

Within the first 5 years of disease onset, infection and active SLE account for over 80% of deaths in lupus. Despite a significant reduction as a cause of death over time, infection remains the single biggest killer in those with disease over 20 years. The importance of atherosclerosis as a cause of death increases over time and replaces active SLE as the next most important cause of death in lupus patients with increasing disease duration.


Disclosure:

B. J. Sheane,
None;

D. Ibanez,
None;

D. D. Gladman,
None;

M. B. Urowitz,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/causes-of-mortality-in-lupus-patients-followed-prospectively-at-a-large-single-centre-lupus-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology